NextFin News - Alamar Biosciences Inc. priced its initial public offering at the top of an increased range late Thursday, raising $191 million as investors signal a renewed appetite for high-growth precision diagnostics. The Fremont, California-based company sold 10.6 million shares for $18 each, according to people familiar with the matter who asked not to be identified because the information is not yet public. The final pricing exceeded the company’s earlier marketing terms, which sought to sell 9.38 million shares at a range of $15 to $17.
The upsized offering values the proteomics specialist at approximately $1.2 billion, a significant milestone for a commercial-stage firm that has seen its revenue nearly triple over the past year. Alamar’s proprietary NULISA technology and its ARGO HT System have gained rapid traction in the research community, providing scientists with the ability to detect low-abundance protein biomarkers that were previously difficult to isolate. This technical edge translated into $74.2 million in revenue for 2025, representing a 195% increase from the prior year.
The success of the Alamar debut reflects a broader, albeit cautious, reopening of the biotech and medical device IPO window. While the 2024 and 2025 markets were characterized by extreme selectivity, Alamar’s ability to price above its range suggests that institutional investors are willing to pay a premium for companies with proven commercial "pull-through." The company reported an average annual pull-through of more than $400,000 per instrument for its installed base of over 100 units by the end of 2025.
However, the aggressive valuation also brings heightened expectations. Some market observers, including analysts at boutique healthcare research firms, have noted that Alamar’s valuation-to-revenue multiple is now pushing toward the upper decile of its peer group. While the growth trajectory is steep, the company remains in a heavy investment phase, with proceeds from the IPO earmarked for working capital and continued capital expenditures to scale its manufacturing and sales operations.
The offering was led by J.P. Morgan, Bank of America, and TD Cowen. The shares are expected to begin trading Friday on the Nasdaq Global Select Market under the ticker symbol ALMR. The underwriters have a 30-day option to purchase up to an additional 1.59 million shares to cover over-allotments, which could further increase the total proceeds. As the company transitions to the public markets, the primary challenge will be maintaining its triple-digit growth rate while navigating the competitive landscape of the proteomics industry, where larger incumbents are also racing to enhance their biomarker detection capabilities.
Explore more exclusive insights at nextfin.ai.
